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Summary
Ovarian cancer (OC) is most often contained within the peritoneal cavity, making it an ideal 
disease for adenoviral-delivered gene therapies. In effort to develop a safe and effective gene 
therapy for OC, we created a replication deficient adenovirus bearing the herpes simplex 
thymidine kinase (HSV-tk) gene under direction of the tumor specific promoter human epididymis 
protein 4 (HE4). The purpose of this study was to investigate the ability of our adenoviral 
construct to transduce OC cells in vitro and mediate transgene expression of HSV-tk, thereby 
sensitizing OC to the pro-drug ganciclovir. Cisplatin-sensitive (CS) and -resistant (CR) A2780 OC 
cells, infected with virus for 6 hours at 100, 500, and 1000 multiplicity of infection followed by 
ganciclovir treatment every other day for 5 days, were assayed for cell viability. Adenoviral-
mediated transgene expression increased with increasing amounts of virus and peaked at 48 hours 
after transduction in both A2780-CS and -CR. Unexpectedly, ganciclovir alone was slightly toxic 
to both A2780 cell lines (IC50 of 234.9 μg/mL and 257.2 μg/mL in A2780-CS and –CR, 
respectively). Transduction with ADV-HE4-HSV-tk followed by ganciclovir treatment increased 
(P<0.05) cell killing up to ten-fold, lowering the IC50 to 23.9 μg/mL and 32.6 μg/mL in A2780-CS 
and –CR, respectively, at 1000 multiplicity of infection. The results support the potential use of 
this approach as a gene therapy for OC, a disease that accounts for more deaths than any other 
cancer of the female reproductive system.
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Ovarian cancer (OC) continues to be the deadliest of the gynecologic cancers. Despite 
continued research and technological advances, the standard treatment for OC has remained 
essentially unchanged, consisting of surgical de-bulking followed by treatment with 
platinum-based chemotherapies. Although most OC patients initially respond to current 
treatments, the large majority of patients experience fatal relapses as a result of chemo-
resistance (Vaughan et al, 2011). Due to lack of symptoms and routine screening, the vast 
majority of OC cases are not diagnosed until they have already progressed to advanced 
stages resulting in a relative 5-year survival rate of less than 30% (Howlader N, 1975-2010).
Gene therapy, widely considered a promising treatment in the fight against cancer (Lam et 
al, 2013), specifically targets and kills cancer cells with minimal toxicity to normal cells. In 
particular, the herpes simplex virus thymidine kinase (HSV-tk) is a well-known suicide gene 
which has the ability to preferentially mono-phosphorylate the pro-drug ganciclovir (GCV) 
(Elion et al, 1977). GCV can then be further di- and triphosphorylated by host kinases 
allowing incorporation into elongating DNA chains resulting in chain termination and 
apoptosis (Freeman et al, 1993). Furthermore, GCV-triphosphate is often transferred to 
neighboring cells via gap junctions, a phenomenon known as the bystander effect, resulting 
in cell death when as little as 10% of the cell population is HSV-tk positive (Mesnil and 
Yamasaki, 2000). While the overall effectiveness of HSV-tk/GCV has been demonstrated 
(Dey and Evans, 2011; Fillat et al, 2003), limitations include inefficient gene delivery and 
lack of tumor specificity.
OC is most often contained within the abdominal cavity making it an ideal candidate for 
intraperitoneal delivery of recombinant viral vectors (Kim et al, 2012). Adenoviral vectors 
(ADV) have the ability to infect a broad range of dividing and non-dividing cells and are 
considered safe due to lack of chromosomal integration. ADV also offers a large cloning 
capacity (up to 8kb) and the ability to facilitate gene expression in as little as 12 hours after 
infection. The proficiency of ADV to infect cells is dependent upon the presence of 
coxsackievirus and adenovirus receptor (CAR) of which many tumor cells including OC 
cells express low levels (Kim et al, 2002). However, CAR-independent gene transfer can be 
mediated by the incorporation of an Arg-Gly-Asp (RGD) peptide on the fiber knob, which 
allows the virus to utilize an alternative receptor during the cell entry process resulting in 
more efficient transduction (Dmitriev et al, 1998). In order to combine efficient gene 
transfer, safety, and tumor specificity, we created an RGD-modified adenovirus bearing the 
HSV-tk gene driven by an OC-specific promoter.
The human epididymis protein 4 (HE4), normally expressed in the epididymis (Hellstrom et 
al, 2003; Kirchhoff, 1998), is over-expressed in 93% of serous and 100% of endometrioid 
epithelial ovarian cancer (Drapkin et al, 2005). HE4 has been shown to play an important 
role in OC cell adhesion and motility (Lu et al, 2012). Additionally, a specific region of the 
HE4 promoter (-530 bp from the ATG start site) was shown to be highly transcriptionally 
active in various OC cell lines with minimal activity in normal tissue (Berry et al, 2004). 
This region of the HE4 promoter has successfully been used to drive expression of a deadly 
toxin in mice bearing ovarian tumors resulting in decreased tumor burden and extended 
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survival (Huang et al, 2009). HE4 has recently been identified as an early detection 
biomarker for OC (Moore et al, 2008). In conjunction with the typically used CA125, HE4 
has aided in distinguishing between benign and malignant tumors, predicting OC 
progressiveness, and been shown to correctly diagnose the aggressive type II EOC at all 
stages and ages (Kalapotharakos et al, 2012; Kristjansdottir et al, 2013; Lin et al, 2012; 
Steffensen et al, 2012; Trudel et al, 2012). Based on these findings, the HE4 promoter may 
be a promising gene therapy approach tailored specifically toward patients with high serum 
levels of HE4. Toward this objective, the goal of the current study was to examine the 
ability of our ADV-HE4-HSV-tk construct to efficiently transduce OC and drive expression 
of HSV-tk, thereby creating a safe and tumor specific gene therapy.
II. Materials and Methods
A. Plasmid construction and sequence verification
The plasmids pDRIVE-hHE4ZeoR and pORF9-HSV1-tkShAmpR were purchased (InvivoGen, 
San Diego, CA) and double-digested with restriction enzymes NcoI/NheI, The HSV1-
tk:Shble fragment (1587bp) was ligated into the pDRIVE-hHE4 backbone and double 
digestion confirmed correct size and orientation. PCR was performed using primers (set 1 
forward - 5’CCTGATCCTGGGGGATT GTG and set 1 reverse - 5’GCAGTAGCGTG 
GGCATTTTC, and set 2 forward - 5’CGA GGAGCAGGACTGACC and set 2 reverse - 
5’ATACCTGTCCGCCTTTCTCC) for verification of cloning. Samples were prepared and 
validated (100% match, correct orientation, no insertions/ deletions) by sequencing at the 
ISU Molecular Research Core Facility (Applied Biosystems 3130XL Capillary DNA 
Sequencer, Pocatello, ID).
B. Adenovirus construction and fluorescent imaging
A replication deficient (DE1/E3) and fiber modified (RGD) marker human adenovirus type 
5 (ADV-CMV-GFP, 1×1010 PFU/mL) was used (Vector Biolabs, Philadelphia, PA) to test 
infection in OC cells. To create ADV-HE4-tk, pHE4-HSV1-tk:Shble (2506 bp) was excised 
using SpeI/SwaI, gel purified, then ligated into the DUAL-BASIC-EGFP Shuttle Vector 
(provided by Vector BioLabs) that had been linearized with BAMHI/XbaI. Production and 
purification of ADV-HE4-tk (3.5×1010 PFU/mL) was carried out by Vector BioLabs. Cells 
were seeded at 20,000cells/35mm2 dish, then infected the next day with 10 to 1000 MOI. 
After 24 hours, virus-infected media was replaced with fresh media and live images of cells 
expressing GFP were taken using a fluorescent confocal microscope (Fluoview, FV10i, 
Olympus) at 24, 48, and 72 hours after infection. Constant image parameters were 
maintained.
C. Cell culture, drug treatment, and cell toxicity assays
All cells were maintained in RPMI 1640 media (Corning Cellgro) containing 10% FBS and 
2mM L-glutamine, 100U/mL penicillin and 100μg/mL Streptomycin (Corning Cellgro), at 
37°C and 5% CO2. Cisplatin-sensitive and -resistant A2780 OC cells were described 
previously (Li et al, 2009). Ganciclovir (GCV; InvivoGen) was reconstituted to 10 mg/mL 
according to manufacture specifications for use in cell viability assays; cells were seeded at 
1,000 cells/well in 100uL media on 96-well plates (polystyrene flat-bottom w/lid, tissue 
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culture treated, Falcon) and infected the following day with 100, 500, or 1000 MOI for 6 
hours, then virus media was removed and replaced with media containing GCV (from 10 to 
200 μg/mL). Fresh GCV was added every other day. Toxicity assays using WTS-8 [2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetazolium, 
monosodium salt] (CCK-8 kit, Dojindo Laboratories, Santa Clara, CA) were performed on 
day 6. Absorbance was read at 450nm using a BioTek ELx800 microplate reader. Values 
were normalized to the average of untreated cells. All assays were performed independently 
in at least duplicate.
Prism software was used for graphing and statistical analysis (two-factor ANOVA analysis). 
All IC50 calculations were made by plotting log (inhibitor) vs. normalized response with a 
variable slope for P<0.05 (degrees freedom = 22).
D. Western blot analysis of HSV-tk protein expression
Cells were seeded at 250,000 cells/10 cm2 dish, allowed to incubate for a day, then infected 
the following day with ADV-HE4-tk at 100, 500, or 1000 MOI. After 48 hours, cells were 
pelleted for protein isolation and quantification (BioRad DC Protein Assay). Samples were 
diluted to the same concentration, mixed 5:1 using 5X SDS loading buffer, heated at 95°C 
for 5min, then 15 μL loaded and run on 12% bis-acrylamide gel using BioRad Miniprotein 
box. Samples were transferred to a nitrocellulose membrane, blocked (5% non-fat milk in 
TBS-T (.05% Tween) for 1 hour at room temperature, washed, and incubated with primary 
antibodies overnight at 4°C (HSV-1 Thymidine Kinase; cat: sc-28037, 1:200 dilution or 
GAPDH; cat: sc-25778, 1:500 dilution, Santa Cruz, Dallas, TX). Membranes were incubated 
(1 hour at RT) with secondary antibodies (HRP donkey anti-goat IgG, sc-2020, 1:2000 
dilution, Santa Cruz or HRP goat anti-rabbit, #31460, 1:5000 dilution, Fisher), washed, 
incubated for 5 min. using BioRad Clarity Western ECL Substrate, and imaged (inverse 
digital images shown) side by side for chemiluminescence using a Gel Logic 2200 and 
Carestream Molecular Imaging Software.
III. Results and Discussion
In order to develop a potential gene therapy for OC, we utilized the HE4 promoter to drive 
expression of HSV-tk. An RGD-modified adenovirus was chosen as the mechanism of 
delivery in vitro. Experiments were carried out using the A2780 OC cell line, which was 
previously used in other studies that employed the HE4 promoter to drive high exogenous 
protein expression (Berry et al, 2004; Huang et al, 2009). Another advantage to using the 
A2780 cells was the availability of both cisplatin-sensitve (CS) and –resistant (CR) cell 
lines, which allowed us to test our construct in an aggressive drug-resistant model (Li et al, 
2009). Once infectivity and viral-mediated HSV-tk expression were confirmed, cell viability 
assays were performed to evaluate the cell killing ability of ADV-HE4-HSV-tk upon 
treatment with GCV.
A. Adenoviral transduction
Initially, the marker ADV-CMV-GFP (Figure 1A) was tested in A2780-CS and A2780-CR 
cells, to demonstrate feasibility of the adenovirus to transduce OC cells and produce 
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sufficient gene expression. GFP expression in cells transduced with ADVCMV-GFP was 
observed as early as 12 hours after infection at as little as 10 MOI, yet the highest (P<0.5) 
GFP expression was achieved using 1000 MOI (Figure 2A). The percent of cells expressing 
GFP increased (P<0.5) with increasing MOI in a titre-dependent manner (Figure 2A). No 
visible difference was detected in the ability of the ADV-CMV-GFP to infect and mediate 
GFP expression in A2780-CS versus -CR.
Once it was established that the marker adenovirus could successfully infect and mediate 
GFP expression, similar infectivity experiments were carried out using the ADVHE4-HSV-
tk construct (Figure 1B), which also contained the GFP marker gene. Transduction with the 
ADV-HE4-HSV-tk construct yielded similar results in both cell lines, and the percentage of 
cells expressing GFP increased (P<0.05) with increasing MOI (Figure 2B). By examining 
the ADV-HE4-tk mediated expression of GFP over time and at increasing MOI, we were 
able to determine that the highest (P<0.05) GFP expression occurred using 1000 MOI at 48 
hours after infection (Figure 3). Thus, the expression of HSV-tk under direction of the HE4 
promoter should similarly peak around 48 hours. Western blot analysis for HSV-tk 
expression in both A2780 cell lines, performed 48 hours after infection with ADV-HE4-tk, 
confirmed that HE4 promoter driven HSV-tk expression was present and increased with 
increasing MOI (Figure 4).
B. Cell Viability Assays
Toxicity assays were performed to assess the effect of ADV-HE4-tk on the A2780 cells 
without drug treatment. The percent viability of cells transduced using 100, 500, or 1000 
MOI of ADV-HE4-tk decreased only slightly as the MOI increased (Figure 5A). The 
ADVHE4-tk incubation time (from 6 hours up to 24 hours incubation time) had no 
discernible effect on viability, and the virus was minimally toxic up to 1000 MOI.
Surprisingly, treatment of both cell lines with GCV alone (Figure 5B) resulted in significant 
(P<0.05) cell death. Because GCV is recognized as a non-toxic pro-drug and converted into 
the monophosphate form only in the presence of herpes simplex viral thymidine kinases, we 
examined the A2780 cell lines for basal (endogenous) HSV-tk expression using whole 
transcriptome analysis, as described previously (Miller et al, 2013). The results revealed a 
low level of HSV1-tk and HSV2-tk in both the A2780-CS and –CR (supplemental figure 1). 
A search of the literature revealed only one paper that briefly (table 1 legend) mentioned 
sensitivity of A2780 cells to GCV alone (Selvakumaran et al, 2001). OC cell lines are not 
typically tested for Herpes Simplex Virus by the ATCC or the ECACC, yet our findings 
suggest epithelial derived cell lines may in fact be positive for the virus and should be tested 
for HSV-tk expression when performing studies using the HSV-tk/GCV system.
Despite results indicating OC sensitivity to GCV, the effect of GCV treatment in 
combination with ADV-HE4-HSV-tk was examined. We were able to further sensitize the 
A2780-CS as well as A2780-CR to GCV (Figure 6 & Table 1) resulting in decreased IC50 
upon transduction with virus (Table 1). The IC50 in A2780-CS cells decreased (P<0.05) 
from 257 μg GCV/mL to 33 μg GCV/mL (7.9-fold decrease) upon transduction with 1000 
MOI using ADV-HE4-tk, and a similar decrease was observed in the IC50 of A2780-CR 
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cells from 234.9 μg GCV/mL to 23.9 μg GCV/mL (9.8-fold decrease). These results indicate 
that the HE4 promoter was transcriptionally active and able to drive HSV-tk expression.
It is concluded that even though low levels of endogenous HSV-tk were already present in 
this particular cell line, the HE4 promoter was accessible and sufficiently active to drive 
further expression of HSV-tk, facilitating increased cell death.
We treated both infected and uninfected A2780 cells with Zeocin. After 6 days, the majority 
of the uninfected cells had died while the cells infected with ADV-HE-tk (using 500 and 
1000 MOI) showed increased ability to survive in the presence of up to 500 μg Zeocin/mL 
(data not shown). The resultant resistance to Zeocin upon transduction with ADV-HE4-tk 
strongly suggested that the HE4 promoter was able to drive HSV-tk:Sh ble expression, and 
that the increased sensitization of A2780 cells to GCV was viral-mediated via the HE4 
promoter, and not solely the presence of endogenous HSV-tk.
IV. Conclusions
We have created an RGD fiber modified adenovirus bearing a potential gene therapy for 
OC. This therapy involves the use of the OC-specific promoter HE4 to drive expression of 
the suicide HSV-tk gene in cisplatin-sensitive and resistant A2780 cells, thus sensitizing the 
OC cells to GCV. We demonstrate that both cell lines are susceptible to adenoviral 
transduction with ADV-HE4-tk, by means of GFP expression as a marker, and exhibit 
cytotoxicity in response to HE4 promoter driven HSV-tk upon treatment with GCV.
The percent cell viability was titre-dependent, with increased cell killing corresponding to 
increased MOI. This adenoviral-delivered therapy is tailored specifically towards being able 
to treat OC patients identified with high levels of serum HE4, which is often an indicator of 
tumor aggressiveness and progression.
Future work involves examining the effectiveness of this therapy in other cell lines that have 
high genetic similarity to high-grade serious OC tumors (Domcke et al, 2013). Positive 
results would merit further testing in vivo by treating mice bearing ovarian tumors with 
intraperitoneal injections of ADV-HE4-tk. In an effort to achieve more sustained transgene 
expression and minimal inflammatory immune response or hepatic toxicity, long term 
studies may also involve the creation of a recombinant adeno-associated virus (Bui Nguyen 
et al, 2010; Lisowski et al, 2012) to deliver the HE4-tk gene.
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Figure 1. Construction of ADV-HE4-tk
(A) A replication deficient (dE1/E3) and RGD fiber modified marker human adenovirus 
type 5 bearing the CMV promoter driven-GFP gene was initially used to test infectivity in 
A2780-CS and -CR ovarian cancer cells. (B) Once infectivity and GFP expression was 
established, ADV-HE4-tk was created by inserting the HE4 promoter-driven HSV1-tk:Shble 
gene.
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Figure 2. Virus-mediated GFP expression with increasing MOI
A2780-CS cells were seeded at (A) 30,000 cells/35mm2 dish, then infected the following 
day with marker ADV-CMV-GFP at various MOI (0, 80, 200, or 1000) or (B) seeded at 
20,000 cells/35mm2 dish, then infected the following day with ADV-HE4-tk at various MOI 
(0, 100, 500, or 1000). After 24 hours, virus media was removed and replaced with fresh 
media, and pictures were taken of live cells using a fluorescent confocal microscope (A) 40x 
magnification (B) 10x magnification. (* indicates statistically different groups, P<.05)
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Figure 3. GFP expression over time with increasing MOI using ADV-HE4-tk
A2780-CS cells were seeded 20,000 cells/35mm2 dish, then infected the following day with 
ADV-HE4-tk. After 24 hours infection time, virus media was removed and replaced w/fresh 
media and pictures were taken of live cells 24, 48, and 72 hours after infection with 0, 100, 
500, or 1000 MOI using a fluorescent confocal microscope, 30x magnification. (*** 
indicates statistically different groups, P<.01)
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Figure 4. HSV-tk:Shble expression in ovarian cancer cells
Western blot analysis was performed on protein isolated from A2780-CS and -CR cells 48 
hours after transduction with ADV-HE4-tk with MOI ranging from 0 to 1000. Cells were 
seeded 250,000 cells per 10cm2 dish and allowed to recover for 24 hours. Virus-infected 
media was added at various MOI, incubated for 48 hours, and western blot analysis was 
performed.
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Figure 5. ADV-HE4-tk viability and GCV sensitivity
A2780-CS and –CR cells were seeded at 1,000 cells/well on 96-well plates. (A) Cells were 
infected on day 2 with ADV-HE4-tk at 100, 500, or 1000 MOI. After 6 hours incubation 
time, virus media was removed and replaced with fresh media. Media was replaced every 
other day. WTS-8 viability test was performed on day 6. (B) Cells were treated with 
increasing concentrations of GCV up to 1000 μg/mL starting 48 hours after seeding. Fresh 
drug was added every other day. WTS-8 viability tests were performed on day 6. 
Absorbance was read at 450 nm, and results show average viability normalized to untreated 
cells. Independent experiments were performed at least in duplicate (number of independent 
samples for each concentration/MOI = 24).
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Figure 6. ADV-HE4-tk sensitizes ovarian cancer cells to GCV
(A) A2780-CS and (B) A2780-CR cells were seeded at 1,000 cells/well on 96-well plates, 
then infected the following day with ADV-HE4-tk at 100, 500, or 1000 MOI. After 6 hours 
incubation time, virus media cells were treated with GCV as indicated. Fresh drug was 
replaced every other day. WTS-8 viability tests were performed on day 6. Absorbance was 
read at 450 nm, and results show the average viability normalized to untreated cells. 
Independent experiments were performed at least in duplicate. (See Table 1 for statistical 
summary of the IC50 values).
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Table 1
IC50 (μg of GCV/mL media) of ADV-HE4-tk transduced cells. A2780-CS and –CR cells were incubated with 
increasing amount of virus for 24 hours, then treated every other day with GCV followed by a WTS-8 cell 
viability test on day 6. Statistical summary of the IC50 values in both A2780-CS and -CR cells from figure 6 
(P=.05).
IC50 95% Confidence Interval Fold Decrease Log IC50 Std. Error Deg. Freedom
A2780-CS
0 MOI 257.2 210.4 to 314.3 2.910 0.043 28
100 MOI 64.6 59.9 to 69.6 4.0 1.816 0.016 28
500 MOI 41.0 37.6 to 44.7 6.3 1.613 0.018 28
1000 MOI 32.6 28.9 to 36.7 7.9 1.513 0.026 28
A2780-CR
0 MOI 234.9 208.3 to 265.0 2.371 0.026 28
100 MOI 87.4 79.5 to 96.0 2.7 1.942 0.020 28
500 MOI 57.9 53.3 to 62.9 4.1 1.763 0.018 28
1000 MOI 23.9 21.0 to 27.1 9.8 1.378 0.027 28
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